Today, LifeBioSciences team confirmed the first patient has been dosed with an epigenetic restoration drug candidate targeting optic neuropathies. "An exciting milestone"
Life BioSciences has announced a significant milestone with the first patient dosed in a Phase 1 clinical trial for ER-100, an epigenetic restoration drug candidate. This drug targets optic neuropathies, a group of disorders that damage the optic nerve and can lead to permanent vision loss. The trial will assess the safety and tolerability of ER-100, while also evaluating its impact on visual function. AI
